Oncimmune Holdings PLC (LON:ONC) said its EarlyCDT lung blood test will be part of a large-scale study in the US to assess its potential use in screening people with low-to-moderate risk lung nodules.
Marketed in the States as Nodify CDT, the Oncimmune technology is being used alongside Nodify XL2 in the clinical assessment being carried out by partner Biodesix.
The ALTITUDE trial will enrol a total of 2,000 with the first batch of 500 expected to be recruited in the first phase.
Oncimmune said researchers wanted to “demonstrate the efficacy” of using the two tests together.
It added that they also wanted to understand the economic impact of the approach in guiding treatment and its potential to reduce healthcare costs.
“Oncimmune is committed to producing further evidence that supports both adoption and reimbursement decisions in the markets where EarlyCDT Lung is available,” said chief executive Adam Hill in a statement
“Part of our agreement with Biodesix in June 2019 was to continue to deliver high-quality evidence in the US market with EarlyCDT Lung.”
He noted that the ALTITUDE study would build on the data presented last week at the American College of Chest Physicians from the PANOPTIC study while contributing to the “substantial evidence base already underpinning the use of our product globally”.